Successful "in-flight" activation of natural killer cells during long-distance shipping

Scott A. Koepsell, Diane M. Kadidlo, Susan Fautsch, Jeffrey McCullough, Hans Klingemann, John E. Wagner, Jeffrey S. Miller, David H. McKenna

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Background: Natural killer (NK) cells have shown promise in the treatment of malignancy. However, the widespread use of these cells may be limited by both the lack of resources and the expertise needed to manufacture them and the apparent need to use only fresh cells. The NHLBI-sponsored Production Assistance for Cellular Therapies group was established to provide the resources and expertise to carry out cell therapy research, including support of clinical trials. Here we describe the qualification of in transit activation of an NK-cell therapy product in preparation for a Phase I clinical trial at a distant medical center. Study design and methods: Nonmobilized apheresis mononuclear cell collections were CD3+ cell depleted, placed into culture bags with interleukin (IL)-2, and shipped from Minneapolis/Saint Paul, Minnesota, to Columbus, Ohio, and back to Minneapolis/Saint Paul, under warm, monitored temperatures. Products underwent quality control (QC) testing including cell count, immunophenotyping, viability, endotoxin, sterility culture, and cytotoxicity assays. One product tested the relative importance of IL-2 and controlled incubation. Results: The length of shipment ranged from 14 to 16 hours, and temperatures were well controlled. QC testing was acceptable based upon previous in-house experience. Controlled incubation was not necessary for successful activation of NK cells, but IL-2 appeared essential. Conclusion: The need for novel cell therapies to be infused as fresh products may be a limitation for various cell types. However, we have shown that NK cells can be successfully shipped in the fresh state (allowing 48 hr from apheresis to product infusion) for use at clinical centers. Although IL-2 is critical for NK-cell activation, a 37°C, 5% CO2 incubator is not.

Original languageEnglish (US)
Pages (from-to)398-403
Number of pages6
JournalTransfusion
Volume53
Issue number2
DOIs
StatePublished - Feb 1 2013

Fingerprint

Natural Killer Cells
Interleukin-2
Cell- and Tissue-Based Therapy
Saints
Blood Component Removal
Quality Control
National Heart, Lung, and Blood Institute (U.S.)
Incubators
Immunophenotyping
Clinical Trials, Phase I
Temperature
Group Psychotherapy
Endotoxins
Infertility
Cell Count
Clinical Trials
Research
Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Hematology

Cite this

Koepsell, S. A., Kadidlo, D. M., Fautsch, S., McCullough, J., Klingemann, H., Wagner, J. E., ... McKenna, D. H. (2013). Successful "in-flight" activation of natural killer cells during long-distance shipping. Transfusion, 53(2), 398-403. https://doi.org/10.1111/j.1537-2995.2012.03695.x

Successful "in-flight" activation of natural killer cells during long-distance shipping. / Koepsell, Scott A.; Kadidlo, Diane M.; Fautsch, Susan; McCullough, Jeffrey; Klingemann, Hans; Wagner, John E.; Miller, Jeffrey S.; McKenna, David H.

In: Transfusion, Vol. 53, No. 2, 01.02.2013, p. 398-403.

Research output: Contribution to journalArticle

Koepsell, SA, Kadidlo, DM, Fautsch, S, McCullough, J, Klingemann, H, Wagner, JE, Miller, JS & McKenna, DH 2013, 'Successful "in-flight" activation of natural killer cells during long-distance shipping', Transfusion, vol. 53, no. 2, pp. 398-403. https://doi.org/10.1111/j.1537-2995.2012.03695.x
Koepsell, Scott A. ; Kadidlo, Diane M. ; Fautsch, Susan ; McCullough, Jeffrey ; Klingemann, Hans ; Wagner, John E. ; Miller, Jeffrey S. ; McKenna, David H. / Successful "in-flight" activation of natural killer cells during long-distance shipping. In: Transfusion. 2013 ; Vol. 53, No. 2. pp. 398-403.
@article{fca7ecb10fc4468d987b8b9c266a56bb,
title = "Successful {"}in-flight{"} activation of natural killer cells during long-distance shipping",
abstract = "Background: Natural killer (NK) cells have shown promise in the treatment of malignancy. However, the widespread use of these cells may be limited by both the lack of resources and the expertise needed to manufacture them and the apparent need to use only fresh cells. The NHLBI-sponsored Production Assistance for Cellular Therapies group was established to provide the resources and expertise to carry out cell therapy research, including support of clinical trials. Here we describe the qualification of in transit activation of an NK-cell therapy product in preparation for a Phase I clinical trial at a distant medical center. Study design and methods: Nonmobilized apheresis mononuclear cell collections were CD3+ cell depleted, placed into culture bags with interleukin (IL)-2, and shipped from Minneapolis/Saint Paul, Minnesota, to Columbus, Ohio, and back to Minneapolis/Saint Paul, under warm, monitored temperatures. Products underwent quality control (QC) testing including cell count, immunophenotyping, viability, endotoxin, sterility culture, and cytotoxicity assays. One product tested the relative importance of IL-2 and controlled incubation. Results: The length of shipment ranged from 14 to 16 hours, and temperatures were well controlled. QC testing was acceptable based upon previous in-house experience. Controlled incubation was not necessary for successful activation of NK cells, but IL-2 appeared essential. Conclusion: The need for novel cell therapies to be infused as fresh products may be a limitation for various cell types. However, we have shown that NK cells can be successfully shipped in the fresh state (allowing 48 hr from apheresis to product infusion) for use at clinical centers. Although IL-2 is critical for NK-cell activation, a 37°C, 5{\%} CO2 incubator is not.",
author = "Koepsell, {Scott A.} and Kadidlo, {Diane M.} and Susan Fautsch and Jeffrey McCullough and Hans Klingemann and Wagner, {John E.} and Miller, {Jeffrey S.} and McKenna, {David H.}",
year = "2013",
month = "2",
day = "1",
doi = "10.1111/j.1537-2995.2012.03695.x",
language = "English (US)",
volume = "53",
pages = "398--403",
journal = "Transfusion",
issn = "0041-1132",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Successful "in-flight" activation of natural killer cells during long-distance shipping

AU - Koepsell, Scott A.

AU - Kadidlo, Diane M.

AU - Fautsch, Susan

AU - McCullough, Jeffrey

AU - Klingemann, Hans

AU - Wagner, John E.

AU - Miller, Jeffrey S.

AU - McKenna, David H.

PY - 2013/2/1

Y1 - 2013/2/1

N2 - Background: Natural killer (NK) cells have shown promise in the treatment of malignancy. However, the widespread use of these cells may be limited by both the lack of resources and the expertise needed to manufacture them and the apparent need to use only fresh cells. The NHLBI-sponsored Production Assistance for Cellular Therapies group was established to provide the resources and expertise to carry out cell therapy research, including support of clinical trials. Here we describe the qualification of in transit activation of an NK-cell therapy product in preparation for a Phase I clinical trial at a distant medical center. Study design and methods: Nonmobilized apheresis mononuclear cell collections were CD3+ cell depleted, placed into culture bags with interleukin (IL)-2, and shipped from Minneapolis/Saint Paul, Minnesota, to Columbus, Ohio, and back to Minneapolis/Saint Paul, under warm, monitored temperatures. Products underwent quality control (QC) testing including cell count, immunophenotyping, viability, endotoxin, sterility culture, and cytotoxicity assays. One product tested the relative importance of IL-2 and controlled incubation. Results: The length of shipment ranged from 14 to 16 hours, and temperatures were well controlled. QC testing was acceptable based upon previous in-house experience. Controlled incubation was not necessary for successful activation of NK cells, but IL-2 appeared essential. Conclusion: The need for novel cell therapies to be infused as fresh products may be a limitation for various cell types. However, we have shown that NK cells can be successfully shipped in the fresh state (allowing 48 hr from apheresis to product infusion) for use at clinical centers. Although IL-2 is critical for NK-cell activation, a 37°C, 5% CO2 incubator is not.

AB - Background: Natural killer (NK) cells have shown promise in the treatment of malignancy. However, the widespread use of these cells may be limited by both the lack of resources and the expertise needed to manufacture them and the apparent need to use only fresh cells. The NHLBI-sponsored Production Assistance for Cellular Therapies group was established to provide the resources and expertise to carry out cell therapy research, including support of clinical trials. Here we describe the qualification of in transit activation of an NK-cell therapy product in preparation for a Phase I clinical trial at a distant medical center. Study design and methods: Nonmobilized apheresis mononuclear cell collections were CD3+ cell depleted, placed into culture bags with interleukin (IL)-2, and shipped from Minneapolis/Saint Paul, Minnesota, to Columbus, Ohio, and back to Minneapolis/Saint Paul, under warm, monitored temperatures. Products underwent quality control (QC) testing including cell count, immunophenotyping, viability, endotoxin, sterility culture, and cytotoxicity assays. One product tested the relative importance of IL-2 and controlled incubation. Results: The length of shipment ranged from 14 to 16 hours, and temperatures were well controlled. QC testing was acceptable based upon previous in-house experience. Controlled incubation was not necessary for successful activation of NK cells, but IL-2 appeared essential. Conclusion: The need for novel cell therapies to be infused as fresh products may be a limitation for various cell types. However, we have shown that NK cells can be successfully shipped in the fresh state (allowing 48 hr from apheresis to product infusion) for use at clinical centers. Although IL-2 is critical for NK-cell activation, a 37°C, 5% CO2 incubator is not.

UR - http://www.scopus.com/inward/record.url?scp=84873450267&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873450267&partnerID=8YFLogxK

U2 - 10.1111/j.1537-2995.2012.03695.x

DO - 10.1111/j.1537-2995.2012.03695.x

M3 - Article

C2 - 22574659

AN - SCOPUS:84873450267

VL - 53

SP - 398

EP - 403

JO - Transfusion

JF - Transfusion

SN - 0041-1132

IS - 2

ER -